When adult-onset inflammation and hematologic abnormalities travel together, the clinical question may need to cross specialty boundaries. VEXAS is one consideration; it should not become a shortcut around a broad differential diagnosis.
Recognize the combination
Consider VEXAS in an appropriate adult phenotype combining systemic inflammation with findings such as macrocytic anemia or other cytopenias, neutrophilic skin disease, chondritis, pulmonary involvement or thrombosis. Individual features are nonspecific. Review the trajectory, treatment exposure and competing explanations.
Ask the right molecular question
The relevant change is somatic UBA1 variation. Discuss sample selection, assay coverage and sensitivity with the laboratory when suspicion is strong. A generic negative inherited-disease panel may not answer the intended question. Interpret the variant, allele fraction and specimen in context rather than treating a report label as self-explanatory.
The NHS genomics resource offers a focused genetics reference. The international ACR guidance addresses patient selection for testing and hematologic evaluation.
Coordinate the blood and inflammatory assessments
Hematology assessment should address cytopenias and possible associated marrow disease. Marrow vacuoles are a clue, not independently diagnostic. A diagnosis of a myeloid disorder needs its own appropriate evaluation and criteria.
Build a shared baseline: clinical manifestations, blood counts and their trajectory, relevant organ assessments, medicines and adverse effects, infections, thrombosis history and functional impact. Obtain prior pathology and molecular reports rather than duplicating tests without reviewing them.
Make ownership explicit
Before a patient leaves, assign responsibility for prescriptions, laboratory review, infection concerns, inflammatory deterioration and communication of changes. A combined problem list is helpful only if the teams know who acts on it.
The optimal treatment depends on the inflammatory and hematologic phenotype, comorbidity, prior response and goals. Consult the full guidance and relevant trials rather than applying one universal drug sequence. Evidence quality and treatment risks should be part of shared decision-making.
A useful referral contains
- Onset and course of inflammatory manifestations.
- Serial blood counts, treatment exposures and inflammatory results.
- Skin, marrow and other pathology reports, when available.
- The complete UBA1 result or the reason testing is being considered.
- Immediate clinical concerns and the question being asked of the receiving team.
Use the assessment and referral checklist and offer the paired patient guide. This summary supports clinical reasoning; it is not a diagnostic score or treatment protocol.
Sources and further reading
General education, not a diagnosis or an individual treatment plan. Use these resources with your own care team. How this website is edited.